Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Cost-utility analysis of sequential therapy with sorafenib followed by regorafenib versus single-line therapies in advanced hepatocellular carcinoma.
Authors
Jamie Grossman
Bayer, Columbus, OH
Jamie Grossman , Chistopher Fawsitt , David Aceituno , Noman Paracha , Kirhan Özgürdal , Howard Thom
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 529)
DOI
10.1200/JCO.2024.42.3_suppl.529
Abstract #
529
Poster Bd #
E16
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A sequential therapy with sorafenib followed by regorafenib against single-line atezolizumab and bevacizumab in advanced hepatocellular carcinoma (HCC): Indirect treatment comparisons (ITC) using the RESORCE study.
First Author: Jamie Partridge
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Treatment of hepatocellular carcinoma with tyrosine kinase inhibitors: Real-world outcomes from the West of Scotland.
First Author: Gregory Naylor
Poster
2021 Gastrointestinal Cancers Symposium
Posttreatment after lenvatinib in patients with advanced hepatocellular carcinoma.
First Author: Keisuke Koroki
Poster
2020 Gastrointestinal Cancers Symposium
Eligibility for second-line therapy in patients with advanced hepatocellular carcinoma (aHCC): A BC Cancer population-based study.
First Author: Erica S. Tsang